Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 11 de 11 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Zost SJ, Parkhouse K, Gumina ME, Kim K, Díaz Pérez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains . Proceedings of the National Academy of Sciences of the United States of America 2017:6 de noviembre. [Ref.ID 102123]
2.Enlace a cita original Cita con resumen
Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lfthus G, Meece JK, Williams JV, Berman L, Breese HC, Monto AS, Griffin MR, Belongia E, Shay DK, for the US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012;55:951-9. [Ref.ID 93145]
3. Cita con resumen
4.Enlace a cita original
Sandbulte MR, Jiménez GS, Boon ACM, Smith LR, Treanor JJ, et al.. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLOS Medicine 2007;4:59. [Ref.ID 79270]
5. Cita con resumen
Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and imunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51. [Ref.ID 76602]
6.Tiene citas relacionadas
Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman F K, Atmar RL, Edelman R, Nolan C M, Belshe RB, for the National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346:1265-74. [Ref.ID 61505]
7.Tiene citas relacionadas Cita con resumen
Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG, for the US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. A randomized controlled trial. JAMA 2000;283:1016-24. [Ref.ID 49520]
8.
Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. Randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-6. [Ref.ID 47152]
9. Cita con resumen
Tasker SA, Treanor JJ, Paxton W B, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:430-3. [Ref.ID 47041]
10.Tiene citas relacionadas Cita con resumen
Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson K G, Bohnen AM, Hirst HM, Keene O, Wightman K, for the GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997;337:874-80. [Ref.ID 34218]
11.
Treanor JJ, Mattison HR, Dumyati G, Yinnon A, Erb S, O'Brien D, Dolin R, Betts RF. Protective efficacy of combined live intranasal influenza A virus vaccines in the elderly. Ann Intern Med 1992;117:625-33. [Ref.ID 18301]
Seleccionar todas
 
 1 a 11 de 11